Lupin receives Form 483 with 2 observations after US FDA inspection at Ankleshwar facility
The US FDA has completed an inspection of Lupin’s Ankleshwar manufacturing facility conducted from March 2 to March 7, 2026, and issued a Form 483 with two observations. The company said it will respond to the regulator within the stipulated timeframe and remains committed to CGMP compliance.